ATRA
Price
$11.50
Change
+$1.50 (+15.00%)
Updated
Jul 21 closing price
Capitalization
68.56M
CLSD
Price
$0.34
Change
-$0.07 (-17.07%)
Updated
Jul 21 closing price
Capitalization
26.34M
27 days until earnings call
Interact to see
Advertisement

ATRA vs CLSD

Header iconATRA vs CLSD Comparison
Open Charts ATRA vs CLSDBanner chart's image
Atara Biotherapeutics
Price$11.50
Change+$1.50 (+15.00%)
Volume$158.78K
Capitalization68.56M
Clearside Biomedical
Price$0.34
Change-$0.07 (-17.07%)
Volume$5.97M
Capitalization26.34M
ATRA vs CLSD Comparison Chart in %
Loading...
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATRA vs. CLSD commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a Hold and CLSD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (ATRA: $11.50 vs. CLSD: $0.34)
Brand notoriety: ATRA and CLSD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 300% vs. CLSD: 1029%
Market capitalization -- ATRA: $68.56M vs. CLSD: $26.34M
ATRA [@Biotechnology] is valued at $68.56M. CLSD’s [@Biotechnology] market capitalization is $26.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileCLSD’s FA Score has 0 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • CLSD’s FA Score: 0 green, 5 red.
According to our system of comparison, ATRA is a better buy in the long-term than CLSD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 4 TA indicator(s) are bullish while CLSD’s TA Score has 4 bullish TA indicator(s).

  • ATRA’s TA Score: 4 bullish, 4 bearish.
  • CLSD’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ATRA is a better buy in the short-term than CLSD.

Price Growth

ATRA (@Biotechnology) experienced а +23.66% price change this week, while CLSD (@Biotechnology) price change was -59.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.39%. For the same industry, the average monthly price growth was +15.71%, and the average quarterly price growth was +33.77%.

Reported Earning Dates

CLSD is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATRA($68.6M) has a higher market cap than CLSD($26.3M). ATRA YTD gains are higher at: -13.599 vs. CLSD (-64.316). ATRA has higher annual earnings (EBITDA): -5.74M vs. CLSD (-19.77M). ATRA (13.8M) and CLSD (13.6M) have equal amount of cash in the bank . CLSD has less debt than ATRA: CLSD (619K) vs ATRA (40.6M). ATRA has higher revenues than CLSD: ATRA (200M) vs CLSD (3.76M).
ATRACLSDATRA / CLSD
Capitalization68.6M26.3M261%
EBITDA-5.74M-19.77M29%
Gain YTD-13.599-64.31621%
P/E RatioN/AN/A-
Revenue200M3.76M5,313%
Total Cash13.8M13.6M101%
Total Debt40.6M619K6,559%
FUNDAMENTALS RATINGS
ATRA vs CLSD: Fundamental Ratings
ATRA
CLSD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3897
P/E GROWTH RATING
1..100
10077
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATRA's Valuation (74) in the Biotechnology industry is in the same range as CLSD (89) in the Pharmaceuticals Major industry. This means that ATRA’s stock grew similarly to CLSD’s over the last 12 months.

ATRA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLSD (100) in the Pharmaceuticals Major industry. This means that ATRA’s stock grew similarly to CLSD’s over the last 12 months.

ATRA's SMR Rating (100) in the Biotechnology industry is in the same range as CLSD (100) in the Pharmaceuticals Major industry. This means that ATRA’s stock grew similarly to CLSD’s over the last 12 months.

ATRA's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for CLSD (97) in the Pharmaceuticals Major industry. This means that ATRA’s stock grew somewhat faster than CLSD’s over the last 12 months.

CLSD's P/E Growth Rating (77) in the Pharmaceuticals Major industry is in the same range as ATRA (100) in the Biotechnology industry. This means that CLSD’s stock grew similarly to ATRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRACLSD
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
77%
Momentum
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 14 days ago
82%
Declines
ODDS (%)
Bearish Trend 26 days ago
87%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
75%
Aroon
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ILKAF3.600.12
+3.45%
Iluka Resources Ltd.
IDKFF0.05N/A
N/A
ThreeD Capital Inc.
SMTEF6.38N/A
N/A
Smart Eye
TEVJF17.80N/A
N/A
Teva Pharmaceutical Industries Ltd.
GMLPF0.90-0.10
-10.00%
Golar LNG Partners LP

ATRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATRA has been loosely correlated with GRI. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATRA
1D Price
Change %
ATRA100%
+15.00%
GRI - ATRA
40%
Loosely correlated
+9.34%
SLRX - ATRA
39%
Loosely correlated
+18.09%
FULC - ATRA
35%
Loosely correlated
-7.19%
FOLD - ATRA
34%
Loosely correlated
-3.82%
ABCL - ATRA
33%
Loosely correlated
+15.21%
More

CLSD and

Correlation & Price change

A.I.dvisor tells us that CLSD and ACLX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLSD and ACLX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLSD
1D Price
Change %
CLSD100%
-17.11%
ACLX - CLSD
28%
Poorly correlated
+2.67%
INBX - CLSD
28%
Poorly correlated
-9.53%
ATRA - CLSD
27%
Poorly correlated
+15.00%
CUE - CLSD
27%
Poorly correlated
-1.89%
JAZZ - CLSD
26%
Poorly correlated
-0.19%
More